A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days

NCT00964340 | Completed Phase 1

• 1 other identifier: 113312
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective is to determine the pharmacokinetics, safety and tolerability of SRT2104 in healthy elderly subjects following single and 28 days dosing. The secondary objectives of the study are:

1. 1.To contrast changes in leg muscle function following repeat doses of SRT2104 or placebo:
2. 2.To test for a change in the ratio of visceral to subcutaneous body fat following repeat doses of SRT2104 relative to placebo using MRI
3. 3.To estimate any changes in insulin sensitivity (using mOGTT) following repeat doses of SRT2104 or placebo
4. 4.To test for dose-related effects on the exploratory pharmacodynamic measures above

Conditions

Atrophy, Muscular

Outcome Measures

Primary Outcomes (2)

• Determine the pharmacokinetics of SRT2104 in healthy elderly subjects following single and 28 days dosing.

  PK samples will be collected on Days 1 and 28 at pre-dose and at 15 min, 30 min, and 1, 2, 3, 4, 8, 12 hrs post-dose. PK samples will also be collected 24 hrs post-dose on Days 2 and 29.

• Safety and tolerability of SRT2104 in healthy elderly subjects following single and 28 days dosing.

  Safety will be monitored by AEs, VS, physical exam, labs and ECGs during the study.

Secondary Outcomes (4)

• Contrast changes in leg muscle function following repeat doses of SRT2104.

  On Day -1 and Day 27, 31P MRS will measure mitochondrial oxidative capacity in the gastrocnemius muscle of the dominant leg; exercise in the MR scanner and a staged bicycle exercise test will record the exercise endurance tolerance.

• Test for a change in the ratio of visceral to subcutaneous body fat by MRI following repeat doses of SRT2104 or placebo.

  On Day -1 and Day 27 MRI and MRS assessments will be performed to measure compartmental fat distribution.

• Measure changes in insulin sensitivity (using mOGTT) and dose-related effects on pharmacodynamics following repeat doses of SRT2104 or placebo.

  OGTT is measured to assess PD effects of SRT2104 at screening and on Day 29 prior to the administration of 75g of oral glucose, and at 10min, 20min, 30min, 1hr, 1.5hr, 2hr, and 3 hr following glucose administration.

• Test for an increase in overall endurance and activity following repeat doses of SRT2104.

  Pedometer will be worn by subjects while awake for 7 consecutive days from Day -8 until Day -1 and on Day 20 until Day 27.

Study Arms (3)

Placebo

PLACEBO COMPARATOR

The Placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.

Drug: Placebo

0.5g SRT2104

ACTIVE COMPARATOR

The 0.5g SRT2104 treatment group will be administered 2 SRT2104 capsules with 6 matching placebo capsules, for a total of 8 capsules per day. 0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.

Drug: Placebo; Drug: SRT2104

2.0g SRT2104

ACTIVE COMPARATOR

The 2.0g SRT2104 treatment group will be administered 8 SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.

Drug: SRT2104

Interventions

Placebo DRUG

For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.

0.5g SRT2104; Placebo

SRT2104 DRUG

SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.

0.5g SRT2104; 2.0g SRT2104

Eligibility Criteria

• Age: 60 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Independently ambulatory, healthy male and female subjects within the age range of 60 to 80 years (inclusive) at the time of screening
• All female subjects must be of non-childbearing potential. For the purposes of this study, women need to be amenorrheic for at least 12 consecutive months, at least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy) or post tubal ligation. Menopausal status will be confirmed by demonstrating levels of follicle stimulating hormone (FSH) 40 - 138 mIU/ml and oestradiol \<20 pg/ml at entry. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH and/or oestradiol levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at the discretion of the Principal Investigator with agreement of the independent Medical Monitor
• All male subjects must agree with their partners to use double-barrier birth control or abstinence while participating in the study and for 12 weeks following the last dose of study drug
• Willingness to provide written informed consent to participate in the study
• Body Mass Index (BMI) 18-30 kg/m\^2 (inclusive)
• No prior history of HIV 1 or 2
• No prior history of disease markers for hepatitis B \& C virus
• Absence of significant disease or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or physical examination during screening; normal end organ function at the discretion of the Principal Investigator
• Have a normal 12-lead ECG or one with changes considered to be clinically insignificant on medical review. QTcF must be \<430msec for males and \<450msec for females
• Resting supine BP \<160/90 mmHg.
• Comprehension of the nature and purpose of the study and compliance with the requirement of the entire protocol
• Able to communicate in person and by telephone in a manner that allows all protocol procedures to be carried out safety and reliably in the opinion of the investigative site staff
• Able to take 8 capsules of study medication

You may not qualify if:

• Limitation to free passive or active movement of leg or foot by pain, prior injury, or developmental abnormality
• Any major illness in the past three months or any ongoing chronic medical illness which in the opinion of the PI or Medical Monitor could risk subject safety or interpretation of the results
• Ongoing or chronic history of renal or liver impairment, defined as serum creatinine clearance level less than 80ml/min as determined by Cockcroft-Gault formula (adjusted for ideal body weight), and greater than two times the upper limit of normal for liver enzymes, respectively
• Subjects with a CPK\> upper limit of normal. CPK values that are marginally above the upper limit of normal may be retested at the discretion of the Principal Investigator in conjunction with the Sponsor's approval
• History, within 3 years, of drug abuse (including but not limited to anxiolytics or pain medication)
• History of alcoholism (more than two years), drinkers of more than three units per day (one unit of alcohol is equivalent to one small glass of wine, half pint of beer or one measure of spirit)
• Participation in any clinical trial with an investigative medicinal product within the past three months prior to the first dose in the current study
• Exposure to more than three new chemical entities within 12 months prior to the first dose in the current study
• History of difficulty in donating blood or accessibility of veins in left or right arm
• Donation of blood (one unit or 350 ml) within three months prior to receiving the first dose of test material
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation
• Ongoing, or history of endocrine, inflammatory, cardiovascular (in particular cardiac hypertrophy or cardiac dysrrhythmia, cardiac failure or history of prolonged QT interval), gastro-intestinal (except for appendectomy), neurological, psychiatric or metabolic disease which in the opinion of the Investigator or Medical Monitor could risk subject safety or interpretation of the results
• Active neoplastic disease or history of neoplastic disease (except for basal cell carcinoma of the skin)
• Contraindications to MRI including, but not limited to: intracranial aneurism clips (except Sugita), history of metal lathe work or possibility of intra-orbital metal fragments, pacemakers and non-MR compatible heart valves or other non-MR compatible implants, history of claustrophobia or subject feels unable to lie still on their back for a period of 1 hour in the MRI scanner
• Subjects receiving steroids, estrogens insulin or creatine will be excluded. Other concomitant medications and herbal products administered in a stable dose for at least 3 months may be permitted at the discretion of the Principal Investigator

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

London, W12 0HS, United Kingdom

Location

Related Publications (1)

• Libri V, Brown AP, Gambarota G, Haddad J, Shields GS, Dawes H, Pinato DJ, Hoffman E, Elliot PJ, Vlasuk GP, Jacobson E, Wilkins MR, Matthews PM. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One. 2012;7(12):e51395. doi: 10.1371/journal.pone.0051395. Epub 2012 Dec 20.

  PMID: 23284689 BACKGROUND

Related Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
• Results for study 113312 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Muscular Atrophy

Interventions

SRT2104

Condition Hierarchy (Ancestors)

Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 20, 2009
• First Posted: August 24, 2009
• Study Start: October 1, 2009
• Primary Completion: April 27, 2010
• Study Completion: April 27, 2010
• Last Updated: June 16, 2017

Record last verified: 2017-06

Data Sharing

• IPD Sharing: Will share

Locations

GB (1)